The APOBEC3A Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human liver adenocarcinoma cell line SK-HEP-1. This product is designed to disrupt the APOBEC3A gene, providing a loss-of-function model for investigating APOBEC3A-dependent processes in a hepatic cancer context. The polyclonal format preserves genetic heterogeneity while eliminating APOBEC3A protein expression, enabling robust functional studies. The knockout was generated using CRISPR/Cas9 technology to introduce targeted gene disruption, offering a versatile tool for examining APOBEC3A-mediated cytidine deaminase activity and its broader cellular consequences.
The host cell line SK-HEP-1 originates from the ascites of a liver adenocarcinoma patient and displays a unique hybrid phenotype with both epithelial and endothelial characteristics. Notably, these cells express endothelial markers such as von Willebrand factor, and they serve as a well-established model for liver cancer biology, angiogenesis, and metastasis research. SK-HEP-1 cells are particularly valuable for studying the interplay between tumor cells and the vasculature, and their hepatic origin makes them relevant for investigations of hepatocellular carcinoma biology. This knockout derivative thus provides a platform to dissect gene function in a cell line that bridges cancer and endothelial biology.
APOBEC3A is a potent cytidine deaminase that converts cytidine to uridine in single-stranded DNA, linking innate antiviral immunity to cancer-associated mutagenesis. Its expression is induced by interferon-??/?? and interferon-?? via the JAK-STAT pathway, with transcription mediated by STAT1/STAT2/IRF9 complexes downstream of IFNAR, and is further modulated by NF-??B and TNF-??. APOBEC3A interacts with PCNA and RPA to access replication forks and other ssDNA substrates. The resulting uracil bases are excised by UNG, creating abasic sites processed by APE1, leading to DNA strand breaks and activation of the ATM/ATR-dependent DNA damage response, marked by ??-H2AX. This repair process can result in mutagenic hotspots in genes like PIK3CA and TP53, while in viral infections, APOBEC3A hypermutates viral genomes, restricting pathogens such as HBV and HIV-1, though HIV-1 Vif can counteract this activity.
In the SK-HEP-1 liver cancer model, APOBEC3A knockout provides critical insights into the enzyme’s dual role in innate immunity and genomic instability. Liver cancers frequently harbor an APOBEC mutational signature, and APOBEC3A has been implicated in driving mutations in oncogenes such as PIK3CA and TP53. By disrupting APOBEC3A, these polyclonal cells allow researchers to decipher the contribution of APOBEC3A to tumor evolution under inflammatory conditions, such as those triggered by viral hepatitis or cytokine exposure. Moreover, the SK-HEP-1 background permits concurrent analysis of endothelial-like properties and cancer cell behavior, making the knockout suitable for studying APOBEC3A’s impact on angiogenesis, migration, and metastasis.
This knockout cell population enables a wide array of functional assays, including western blotting, RT-qPCR, RNA-seq, immunofluorescence, ??-H2AX staining, comet assay, cell proliferation, migration, and viral infection assays. These tools support investigations into APOBEC-mediated mutagenesis, innate immune signaling, and antiviral drug target validation in a liver cancer context. For additional information, please contact Ascent Research.
